State Profile for FY 2018 for Dialysis Patients and Facilities - STATE SAMPLE

Transcription

1 Dear State Surveyor: State Profile for FY 2018 for Dialysis Patients and Facilities - STATE SAMPLE This report is designed to provide a comparative summary of treatment patterns and patient outcomes for End Stage Renal Disease (ESRD) patients in this state, as compared to all patients in the. The statistics reported here include dialysis patients treated during in the chronic dialysis facilities in this state and are based primarily on Medicare claims and data collected for CMS. Selected statistics from this profile are summarized below and state-to-state comparisons of key statistics are provided in the Maps and Tables of Key Statistics by State. ESRD CORE Pre-Survey Data Tool For each facility in your state, key data elements from the DFR reviewed in the Core Survey Pre-survey Preparation task are reported in xxx_fy2018_presurvey_ pdf available on the secure Dialysis Reports website ( Narrative text to assist in interpretation is included on the form and bookmark links allow you to jump to a desired facility s report. We hope this profile is of interest to you and is helpful in your survey efforts. We welcome your feedback on ways to improve future profiles. For a complete description of the methods and data reported here please see the Guide to the State Profiles for FY The Guide is available on the Dialysis Data website at What's New This Year As part of a continuing effort to improve the quality and relevance of this report for your state, the following changes have been incorporated into the State Profile for FY 2018: Liver disease as a cause of death has been added to Table 3; Table 9 now include serum albumin summaries from CROWNWeb and Table 10 reports the percentage of patients with hypercalcemia as defined by an uncorrected serum or plasma calcium value greater than 10.2 mg/dl. Facility Highlights Patient Characteristics: On December 31 st, 2016, 12% of patients for this state were treated in a nursing home during the year, compared to 15% nationally. See Table 1 for detailed summaries of all patients treated during in this state. Form CMS-2728 collected data from 13,570 incident patients in this state in Table 2 describes certain important characteristics of these patients at the time of their first outpatient dialysis session, including patients' demographics, medical coverage, primary cause of ESRD, modality, pre-treatment nephrological care, transplant options, and vascular access type. In 2016, the average age of patients in this state was 64 years, compared to the national average of 64 years. Asian patients made up 17% of the patients in this state compared to 5% nationally. 87% of incident patients in this state were informed of their transplant options, compared to 87% nationally. Also in 2016, 21% of incident patients in this state were not under the care of a nephrologist prior to ESRD therapy, compared to 21% nationally. Mortality: There were 9,061 deaths among the patients treated in this state during 2016, while 9,318 would be expected based on their age, race, ethnicity, sex, diabetes status, duration of ESRD, nursing home status, BMI at incidence, comorbidities at incidence, as well as state population death rates. The Standardized Mortality Ratio (SMR) of observed to expected deaths is 0.97, which is 3% lower than expected. Of the deaths in this state in 2016, 20% were preceded by withdrawal from dialysis, compared to the national average of 25%. See Table 3 of this profile for more detailed mortality statistics during in this state. First Year Mortality: There were 2,401 deaths among the incident patients treated in this state during 2015, while 2,367 would be expected based on their age, race, ethnicity, sex, diabetes status, nursing home status, BMI at incidence, comorbidities at incidence, as well as state population death rates. The First Year Standardized Mortality Ratio (SMR) of observed to expected deaths is 1.01, which is 1% higher than expected. Of the deaths among incident patients in this state in 2015, 23% were preceded by withdrawal from dialysis, compared to the national average of 27%. See Table 3 of this profile for more detailed first year mortality statistics during in this state. Produced by The University of Michigan Kidney Epidemiology and Cost Center (August 2017) 1/15

2 Hospitalization: The Standardized Hospitalization Ratio (SHR) of observed to expected hospital admissions for patients in this state during 2016 is 0.95, indicating that these patients had 5% fewer admissions than expected based on characteristics of patients treated in this state. The Standardized Readmission Ratio (SRR) of observed to expected hospital readmissions in this state during 2016 is 1.00, indicating that these patients had the same readmissions as expected. See Table 4 of this profile for additional hospitalization statistics during in this state. Transplantation: 1,552 patients under age 70 in this state during 2016 received their first transplant, while 1,664 would be expected based on the age of these patients. The Standardized Transplantation Ratio (STR) of observed to expected number of patients transplanted for this state is 0.93, which is 7% lower than expected. See Table 5 of this profile for additional transplantation statistics during in this state. Kidney Transplant Waitlist: On December 31, 2016, 31% of the dialysis patients under age 70 being treated in this state were on the kidney transplant waitlist compared to 21% nationally. This difference is statistically significant (p < 0.05) and is unlikely to be due to random chance. See Table 6 of this profile for more information about patients on the kidney transplant waitlist in this state during Influenza Vaccination: On December 31, 2016, 70.7% of the Medicare dialysis patients treated in this state were vaccinated against influenza between August 1 and December 31, 2016, compared to 68.9% nationally. This difference is statistically significant (p<0.05) and is unlikely to be due to random chance. See Table 7 of this profile for more information about vaccinated patients during in this state. Anemia Management: In 2016, 12.1% of hemodialysis patients (with at least 4 eligible Medicare dialysis claims) in this state had an average hemoglobin value below 10 g/dl, compared to 16.6% nationally. Also in 2016, 20.9% of peritoneal dialysis patients (with at least 4 eligible Medicare dialysis claims) in this state had an average hemoglobin value below 10 g/dl, compared to 26.7% nationally. See Table 8 of this profile for additional anemia management statistics in this state during Dialysis Adequacy: Of the eligible hemodialysis patient-months in this state in 2016, 96.0% had a Kt/V >=1.2 reported in Medicare dialysis claims, compared to 96.1% nationally. Of the eligible peritoneal dialysis patient-months in this state in 2016, 88.6% had a Kt/V >=1.7 reported in Medicare dialysis claims, compared to 89.1% nationally. See Table 9 of this profile for more information on dialysis during in this state. Mineral Metabolism: In 2016, 11.4% of eligible patient-months in this state had a serum phosphorus value >=7.0 mg/dl, compared to 12.1% nationally. Also in 2016, 1.4% of eligible patient-months in this state had a calcium uncorrected value >=10.2 mg/dl, compared to 1.5% nationally. See Table 10 of this profile for more mineral metabolism summaries in this state during Vascular Access: In 2016, 65.5% of the prevalent and 18.2% of the incident hemodialysis patients in this state had an arteriovenous (AV) fistula in place. Nationally, 62.9% of the prevalent patients and 17.4% of the incident patients had a fistula in place. Of the prevalent patients receiving hemodialysis treatment in this state, 9.6% had a catheter which had been in place for more than 90 days as their only vascular access, compared to 10.3% nationally. See Table 11 of this profile for additional information about vascular access in this state during Produced by The University of Michigan Kidney Epidemiology and Cost Center (August 2017) 2/15

3 TABLE 1: Summaries for All Dialysis Patients Treated as of December 31 st of each Year *1, a Patients treated on 12/31 of year (n) 55,794 58,311 60,123 61,789 n/a 1b Average age (years) c Age (% of 1a; sums to 100%) < d Female (% of 1a) e Race (% of 1a; sums to 100%) *2 African American Asian/Pacific Islander Native American White Other/Unknown/Missing f Ethnicity (% of 1a; sums to 100%) Hispanic Non-Hispanic Unknown g Cause of ESRD (% of 1a; sums to 100%) Diabetes Hypertension Glomerulonephritis Other/Unknown Missing h Average duration of ESRD (years) i Years since start of ESRD (% of 1a; sums to 100%) < j Nursing facility patients *3 (% of 1a) k Modality (% of 1a; sums to 100%) In-center hemodialysis Home hemodialysis Continuous ambulatory peritoneal dialysis Continuous cycling peritoneal dialysis Other modality * [*1] See Guide, Section IV. [*2] 'Asian' includes Indian sub-continent. 'Native American' includes Alaskan Native. 'White' includes Middle Eastern and Arabian. [*3] Includes patients who were treated at a nursing facility at any time during the year. The source of nursing facility history of patients is the Nursing Home Minimum Dataset. [*4] Other modality includes other dialysis, uncertain modality, and patients not on dialysis but still temporarily assigned to the facility (discontinued dialysis, recovered renal function, and lost to follow up). Produced by The University of Michigan Kidney Epidemiology and Cost Center (August 2017) 3/15

4 TABLE 2: Characteristics of New Dialysis Patients (Form CMS-2728) *1, Patient Characteristics 2a Total number of patients with forms (n) 13,503 13,679 13,941 13,570 n/a 2b Age (average years [0-95]) c Female (% of 2a) d Race *2 (% of 2a; sums to 100%) African American Asian/Pacific Islander Native American White Other/Unknown/Missing e Hispanic (% of 2a) f Primary cause of ESRD (% of 2a; sums to 100%) Diabetes Hypertension Glomerulonephritis Other/Missing g Medical Coverage *3 (% of 2a; sums to 100%) 2h Employer group only Medicare only Medicaid only Medicare and Medicaid only Medicare and Other Other/Unknown None Body Mass Index *4 (Median; Weight/Height^2) 2i Employment *5 Male Female Six months prior to ESRD treatment At first ESRD treatment j Primary Modality (% of 2a; sums to 100%) Hemodialysis CAPD/CCPD Other/Unknown/Missing k Number of incident hemodialysis patients (n) 12,018 12,157 12,255 11,929 n/a 2l Access used at first outpatient dialysis (% of 2k; sums to 100%) Arteriovenous fistula Arteriovenous graft Catheter Other/Unknown/Missing m Arteriovenous fistulae placed (% of 2k) * Average Lab Values Prior to Dialysis *7 2n Hemoglobin (g/dl [3-18]) o Serum Albumin (g/dl [ ]) p Serum Creatinine (mg/dl [0-33]) q GFR (ml/min [0-30]) (continued) Produced by The University of Michigan Kidney Epidemiology and Cost Center (August 2017) 4/15

5 TABLE 2 (continued): Characteristics of New Dialysis Patients (Form CMS-2728) *1, Care Prior to ESRD Therapy 2r Received ESA prior to ESRD (% of 2a) s Pre-ESRD nephrologist care (% of 2a; sums to 100%) No Yes, <6 months Yes, 6-12 months Yes, >12 months Unknown t Informed of transplant options (% of 2a) u Patients not informed of transplant options (n) 1,830 1,840 1,685 1,694 n/a 2v Reason not informed (% of 2u; may not sum to 100%) Medically unfit Unsuitable due to age Psychologically unfit Patient declined information Patient has not been assessed Comorbid Conditions 2w Pre-existing Comorbidity (% yes of 2a) Congestive heart failure Atherosclerotic heart disease * Other cardiac disorder * CVD, CVA, TIA Peripheral vascular disease History of hypertension Diabetes * Diabetes on insulin COPD Current smoker Cancer Alcohol dependence Drug dependence Inability to ambulate Inability to transfer x Average number of comorbid conditions n/a= not applicable. [*1] See Guide, Section V. [*2] 'Asian' includes Indian sub-continent. 'Native American' includes Alaskan Native. 'White' includes Middle Eastern and Arabian. [*3] 'Medicare and Other' excludes patients with Medicare and Medicaid only. 'Other/Unknown' includes patients with unknown status and patients receiving medical benefits under other health insurance plans or plans that are not covered in the categories above. [*4] The median BMI is computed for adult patients at least 20 years old with height, weight, and BMI values in acceptable ranges. Acceptable range for height, weight, and BMI are cm, kg and respectively. [*5] Full-time, part-time, or student (% of year olds). [*6] Includes all patients with AV fistulae, regardless of whether they recieved their hemodialysis treatments using their fistulae. [*7] For continuous variables, all summaries are computed based only on responses in range indicated in brackets for the variable. [*8] 'Atherosclerotic heart disease' includes ischemic heart disease (coronary artery disease) and myocardial infarction. 'Other cardiac disorder' includes cardiac arrest, cardiac dysrhythmia, and pericarditis. 'Diabetes' includes patients with diabetes as the primary cause of ESRD. Produced by The University of Michigan Kidney Epidemiology and Cost Center (August 2017) 5/15

6 TABLE 3: Mortality Summary for All Dialysis Patients ( ) & New Dialysis Patients ( ) *1 Measure Name All Dialysis Patients a Patients (n=number) 73,970 76,884 79,606 81,694 n/a 3b Patient years (PY) at risk (n) 54,429 57,112 59,178 61,345 n/a 3c Deaths (n) 7,876 8,232 8,801 9,061 n/a 3d Expected deaths (n) 8,216 8,504 8,970 9,318 n/a 3e Withdrawal from dialysis prior to death (% of 3c) f Deaths due to infections (% of 3c) g Deaths due to cardiac causes (% of 3c) h Deaths due to liver disease (% of 3c) i Dialysis unrelated deaths *2 (n; excluded from SMR) n/a 3j Standardized Mortality Ratio (SMR; 3c /3d ) k P-value *3.... n/a New Dialysis Patients l Patients (n=number) 13,503 13,679 13,941 n/a 3m Patient years (PY) at risk (n) 12,056 12,240 12,453 n/a 3n Deaths (n) 2,319 2,332 2,401 n/a 3o Expected deaths (n) 2,361 2,359 2,367 n/a 3p Withdrawal from dialysis prior to death (% of 3m) q Deaths due to infections (% of 3n) r Deaths due to cardiac causes (% of 3n) s Deaths due to liver disease (% of 3n) t Standardized Mortality Ratio (SMR; 3n /3o ) u P-value *3... n/a [*1] See Guide, Section VI. [*2] Defined as deaths due to street drugs and accidents unrelated to treatment. [*3] Ratios within the range 0.95 to 1.05 will not have a p-value. A p-value >=0.05 indicates that the ratio is >1.05 or <0.95 plausibly due to random chance. Produced by The University of Michigan Kidney Epidemiology and Cost Center (August 2017) 6/15

7 TABLE 4: Hospitalization Summary for Medicare Dialysis Patients *1, Medicare Dialysis Patients 4a Medicare dialysis patients (n) 50,893 52,325 53,326 54,187 n/a 4b Patient years (PY) at risk (n) 32,797 33,825 34,564 35,003 n/a Days Hospitalized Statistics 4c Total days hospitalized (n) 375, , , ,562 n/a 4d Expected days hospitalized (n) 428, , , ,055 n/a 4e Standardized Hospitalization Ratio for Days (4c/4d) f P-value *2 <0.01 <0.01 <0.01 <0.01 n/a Admission Statistics 4g Total admissions (n) 56,831 56,403 57,768 59,591 n/a 4h Expected total admissions (n) 58,818 59,305 60,816 62,448 n/a 4i Standardized Hospitalization Ratio for Admissions (4g/4h) j P-value * n/a 4k Patients with septicemia (% of 4a) l One day admissions (% of 4g) m Average length of stay (days per admission) Emergency Department(ED) Statistics 4n Total ED visits (n) 84,447 87,827 90,895 94,727 n/a 4o Expected total ED visits (n) 97, , , ,927 n/a 4p Standardized Hospitalization Ratio for ED (4n/4o) q P-value *2 <0.01 <0.01 <0.01 <0.01 n/a 4r Patients with ED visit (% of 4a) s ED visits that result in hospitalization (% of 4p) t Admissions that originate in the ED (% of 4g) Readmission Statistics 4u Index discharges (n) 54,229 53,386 54,354 56,360 n/a 4v Total readmissions (n) 14,309 13,727 14,101 13,495 n/a 4w Expected total readmissions (n) 13,710 13,479 13,736 13,486 n/a 4x Standardized Readmission Ratio (SRR; 4v/4w) [*1] See Guide, Section VII. [*2] Ratios within the range 0.95 to 1.05 will not have a p-value. A p-value >=0.05 indicates that the ratio is >1.05 or <0.95 plausibly due to random chance. Produced by The University of Michigan Kidney Epidemiology and Cost Center (August 2017) 7/15

8 TABLE 5: Transplantation Summary for Dialysis Patients under Age 70 *1, a Eligible patients (n) 50,268 52,051 53,757 55,125 n/a 5b Transplants (n) 1,652 1,607 1,732 1,831 n/a Patients who have not Previously Received a Transplant 5c Eligible patients (n) 46,423 48,088 49,695 51,108 n/a 5d Patient years (PY) at risk (n) 34,396 35,954 37,243 38,638 n/a 5e Actual 1st transplants *2 (n) 1,474 1,409 1,457 1,552 n/a 5f Expected 1st transplants (n) 1,460 1,469 1,552 1,664 n/a 5g Standardized Transplantation Ratio (STR; 5e/5f) h P-value * n/a TABLE 6: Waitlist Summary for Dialysis Patients under Age 70 Treated as of December 31 st of Each Year *1, a Eligible patients on 12/31 (n) 39,925 41,541 42,872 43,294 n/a 6b Patients on the waitlist (% of 6a) c P-value *4 (compared to U.S. value) <0.01 <0.01 <0.01 <0.01 n/a 6d Patients on the waitlist by subgroup (%) *5 Age < Age Male Female African American Asian/Pacific Islander Native American White, Hispanic White, Non-Hispanic Other/Unknown race Diabetes Non-diabetes Previous kidney transplant No previous kidney transplant <2 years since start of ESRD years since start of ESRD years since start of ESRD [*1] See Guide Section VIII (Transplantation) and Section IX (Waitlist). [*2] Among first transplants that occurred after the start of dialysis from , 3.9% of transplants in the U.S. were not included because the transplant occurred less than 90 days after the start of ESRD and 0.9% were not included because the patient was not assigned to a facility at time of transplant. [*3] Ratios within the range 0.95 to 1.05 will not have a p-value. A p-value greater than or equal to 0.05 indicates that the standardized ratio is greater than 1.05 or less than 0.95 plausibly due to random chance. [*4] This state waitlist percentage is compared to the U.S. value for that year: 24.4% (2013), 24.0% (2014), 22.6% (2015), 21.4% (2016). A p-value greater than or equal to 0.05 indicates that the difference between the percent of patients waitlisted in the state and in the nation is plausibly due to random chance. [*5] A missing value indicates that there were no eligible patients in the subgroup.. Produced by The University of Michigan Kidney Epidemiology and Cost Center (August 2017) 8/15

9 TABLE 7: Influenza Vaccination Summary for Medicare Dialysis Patients Treated on December 31 st of Each Year *1, Flu Seasons August 2013-December 2016 Measure Name a Eligible patients on 12/31 (n) 34,319 35,198 35,638 35,630 n/a 7b Patients vaccinated between Aug. 1 and Dec. 31 (% of 7a) c P-value *2 (for 7b compared to U.S. value) *3 <0.01 < <0.01 n/a d Patients vaccinated between Aug. 1 and Mar. 31 of following n/a 73.8 year (% of 7a) 7e P-value *2 (for 7d compared to U.S. value) *4 <0.01 < n/a n/a 7f Patients vaccinated between Aug. 1 and Dec. 31 by subgroup *5 (%) Age < Age Age Age Age Male Female African American Asian/Pacific Islander Native American White Other/unknown race Hispanic < 1 year since start of ESRD years since start of ESRD years since start of ESRD n/a = not applicable [*1] Based on patients with Medicare as primary insurer; see Guide, Section X. [*2] A p-value greater than or equal to 0.05 indicates that the difference between percent of patients vaccinated at the state and national percentage is plausibly due to random chance. [*3] Compared to the U.S. value for that year and time period (08/01-12/31): 71.6% (2013), 73.9% (2014), 73.3% (2015), 68.9% (2016). [*4] Compared to the U.S. value for that year and time period (08/01-03/31): 72.4% (2013), 74.4% (2014), 73.8% (2015). [*5] A missing value indicates that there were no eligible patients in the subgroup Produced by The University of Michigan Kidney Epidemiology and Cost Center (August 2017) 9/15

10 TABLE 8: Anemia Management Summaries for Adult Dialysis Patients *1, Hemoglobin and ESA-CROWNWeb 8a Eligible patients (n) *2 64,568 67,566 70,097 72, ,476 8b Eligible patient-months (n) *3 630, , , ,985 5,212,543 8c Average hemoglobin *4 (g/dl) (average of 8b) d Hemoglobin categories (% of 8b; sums to 100%) <10 g/dl <11 g/dl g/dl >12 g/dl Missing/Out of range e ESA prescribed (% of 8b) Standardized Transfusion Ratio (STrR) 8f Adult Medicare patients (n) 44,765 45,987 46,833 47,607 n/a 8g Patient years (PY) at risk (n) 26,957 27,794 28,230 28,514 n/a 8h Total transfusions (n) 11,457 10,758 10,049 9,622 n/a 8i Expected total transfusions (n) 12,266 11,847 11,335 11,003 n/a 8j Standardized Transfusion Ratio * k P-value * <0.01 <0.01 n/a Hemoglobin-Medicare Claims *7 8l Eligible hemodialysis (HD) patients (n) 28,333 28,816 29,193 28,979 n/a 8m Hemoglobin categories among HD pts (% of 8l; sums to 100%) < 10 g/dl <11 g/dl g/dl > 12 g/dl n Eligible peritoneal dialysis (PD) patients (n) 2,507 2,654 2,703 2,703 n/a 8o Hemoglobin categories among PD pts (% of 8n; sums to 100%) < 10 g/dl <11 g/dl g/dl > 12 g/dl [*1] See Guide, Section XI. Transfusion and claims-based summaries include adult Medicare Dialysis Patients only. [*2] Includes those who switch between HD and PD during the month and patients for whom modality is unknown. [*3] Patients may be counted up to 12 times per year. [*4] Based on in-range values; see Guide for range values. [*5] Calculated as a ratio of observed transfusions to expected transfusions (8h to 8i); not shown if there are fewer that 10 patient-years at risk for transfusions. [*6] Ratios within the range 0.95 to 1.05 will not have a p-value. A p-value greater than or equal to 0.05 indicates that the standardized ratio is greater than 1.05 or less than 0.95 plausibly due to random chance. [*7] Among ESA-treated dialysis patient with ESRD for 90+ days and 4 or more claims at this facility. Produced by The University of Michigan Kidney Epidemiology and Cost Center (August 2017) 10/15

11 TABLE 9: Dialysis Adequacy Summaries for All Dialysis Patients *1, Adult Hemodialysis (HD) Adequacy 9a Eligible HD patients (n) 58,410 60,619 62,784 64,941 n/a 9b Eligible HD patient-months (n) *2 564, , , ,289 n/a 9c Average serum albumin (g/dl) (average of 9b) d Serum albumin categories (% of 9b; sums to 100%) < 3.0 g/dl <3.5 g/dl <4.0 g/dl >=4.0 g/dl Missing e Ultrafiltration rate average *3 (ml/kg/hr) (average of 9b) f Ultrafiltration rate categories (% of 9b; sums to 100%) <=13 (ml/kg/hr) >13 (ml/kg/hr) Missing/Out of range g Eligible HD Kt/V patients (n) *4 *5 53,359 55,014 56,863 59,909 n/a 9h Eligible HD Kt/V patient-months (n) *2 *4 *5 501, , , ,745 n/a 9i Average Kt/V *3 (average of 9h) j Kt/V categories (% of 9h; sums to 100%) < < >= Missing/Out of range Adult Peritoneal Dialysis (PD) Adequacy 9k Eligible PD patients (n) 7,345 8,166 8,619 8,888 61,629 9l Eligible PD patient-months (n) *2 64,489 72,103 76,601 78, ,497 9m Average Weekly Kt/V (average of 9l) *3 * n Weekly Kt/V categories (% of 9l; sums to 100%) *6 < < >= Missing/Out of range o Average serum albumin (g/dl) (average of 9l) p Serum Albumin Categories (% of 9l; sums to 100%) (continued) < 3.0 g/dl <3.5 g/dl <4.0 g/dl >=4.0 g/dl Missing Produced by The University of Michigan Kidney Epidemiology and Cost Center (August 2017) 11/15

12 TABLE 9 (continued): Dialysis Adequacy Summaries for All Dialysis Patients *1, *5 *6 Adult Kt/V--Medicare Claims 9q Eligible Adult HD patients (n) 36,649 37,564 38,385 38,590 n/a 9r Eligible Adult HD patient-months (n) *2 *4 318, , , ,177 n/a 9s Kt/V categories (% of 9r; sums to 100%) < < < < >= Missing/Out of Range/Not Performed/Expired t Adult HD: Kt/V >=1.2 (% of 9r) * u Eligible Adult PD Patients (n) 3,715 4,047 4,105 4,124 n/a 9v Eligible Adult PD patient-months (n) *2 31,177 33,858 34,798 34,733 n/a 9w Kt/V categories (% of 9v; sums to 100%) < < < < >= Missing/Out of Range/Not Performed/Expired x Adult PD: Kt/V >=1.7 (% of 9v) * *5 *6 Pediatric Kt/V --Medicare Claims 9y Eligible Pediatric HD patients (n) n/a 9z Eligible Pediatric HD patient-months (n) *2 * n/a 9aa Kt/V categories (% of 9z; sums to 100%) < < < < >= Missing/Out of Range/Not Performed/Expired ab Pediatric HD: Kt/V >=1.2 (% of 9z) * ac Eligible Pediatric PD Patients (n) n/a 9ad Eligible Pediatric PD patient-months (n) * n/a 9ae Kt/V categories (% of 9ad; sums to 100%) < < < < >= Missing/Out of Range/Not Performed/Expired af Pediatric PD: Kt/V >=1.7 (% of 9ad) * [*1] See Guide, Section XII. Unless otherwise noted, all summaries are based on data reported in CROWNWeb and the patient must be on HD (or PD) for the entire reporting month to be included in patient counts and summaries. [*2] Patients may be counted up to 12 times per year.[*3] Based on in-range values; see Guide for range values.[*4] Kt/V summaries are supplemented with Medicare claims if missing in CROWNWeb. [*5] HD Kt/V summaries are restricted to patients who dialyze thrice weekly. See section of Guide titled Determination of Thrice Weekly for more information. The PD Adequacy section uses the most recent value over a 4-month (adult) or 6-month (pediatric) period. [*6] Kt/V: K = dialyzer clearance of urea; t = dialysis time; V = patient s total body water. Includes Medicare patients who had one eligible dialysis claim submitted by the facility during the year. Based on the value code D5: Result of last Kt/V. Produced by The University of Michigan Kidney Epidemiology and Cost Center (August 2017) 12/15

13 TABLE 10: Mineral Metabolism Summaries for All Adult Dialysis Patients *1, a Eligible adult patients (n) *2 64,568 67,566 70,097 72, ,476 10b Eligible adult patient-months (n) *2 *3 630, , , ,985 5,212,543 10c Average Phosphorous *4 (mg/dl) (average of 10b *5 ) d Phosphorous categories (% of 10b *5 ; sums to 100%) <3.5 mg/dl <4.5 mg/dl mg/dl mg/dl >7.0 mg/dl Missing/Out of range e Average Calcium Uncorrected *4 (mg/dl) (average of 10b) f Calcium Uncorrected categories (% of 10b; sums to 100%) <8.4 mg/dl mg/dl >10.2 mg/dl Missing/Out of range g Average uncorrected serum or plasma calcium > mg/dl (% of 10b *4 *6 ) [*1] See Guide, Section XIII. Summaries are based on data reported in CROWNWeb and the patient must be assigned to the facility the entire month to be included. [*2] Includes patients on ESRD more than 90 days who switch between HD and PD during the month and patients for whom modality is unknown. [*3] Patients may be counted up to 12 times per year. [*4] Based on in-range values; see Guide for range values. [*5] Eligible patients included in the phosphours summaries differ slightly from what is reported in 10b; includes patient-months within the first 90 days of ESRD and excludes those indicating home hemodialysis recieved anytime during the month. [*6] Hypercalcemia is avearaged from uncorrected serum or plasma calcium values over a rolling 3-month period. Produced by The University of Michigan Kidney Epidemiology and Cost Center (August 2017) 13/15

14 TABLE 11: Vascular Access Information for all Adult Dialysis Patients and Access-Releated Infection Summaries for all Medicare Patients *1, Vascular Access 11a Prevalent adult hemodialysis patient months *2 595, , , ,265 n/a 11b Vascular access type in use (% of 11a; sums to 100%) Arteriovenous fistula Arteriovenous graft Catheter Other/Missing c Arteriovenous fistulae placed *3 (% of 11a) d Catheter only >= 90 days *4 (% of 11a) Vascular Access at First Treatment 11e Incident adult hemodialysis patients (n) 12,329 12,392 12,559 12,363 n/a 11f Vascular access type in use (% of 11e; sums to 100%) Arteriovenous fistula Arteriovenous graft Catheter Other/Missing g Arteriovenous fistulae placed *3 (% of 11e) Infection: Peritoneal Dialysis (PD) 11h Eligible PD patients (n) 5,229 5,619 5,867 5,910 n/a 11i Eligible PD patient-months *2 37,109 40,316 41,621 41,798 n/a 11j PD catheter infection rate per 100 PD patient-months * k P-value *6 of 11j (compared to U.S. value *7 ) <0.01 <0.01 n/a n/a = not applicable [*1] See Guide, Section XIV. Vascular Access type is based on data reported in CROWNWeb. For the prevalent summaries (rows 11a-11d), the patient must be assigned to the facility for the entire calendar month to be included. The PD infection summaries are based on Medicare Dialysis claims. [*2] Patients may be counted up to 12 times per year. [*3] Includes all patients with fistulae, regardless of whether or not they received their hemodialysis treatments using their fistulae. [*4] Catheter was used for treatment and has been in place for 90 days or more prior to treatment. Patient does not have a fistula or graft in place. Catheter is only access. Port access devices are reported as catheters for this project. [*5] The ICD-9 PD catheter infection code for PD patients is which is effective thru 9/30/2015 and the ICD-10 PD catheter infection code for PD patients is T8571XA which is effective beginning 10/1/2015. [*6] A p-value greater than or equal to 0.05 indicates the differences between the percent of patients with infection at the facility and national percentage is plausibly due to random change. [*7] Compared to U.S. value for that year: 3.05 (2013), 2.85 (2014), 2.62 (2015), and 1.69 (2016). Produced by The University of Michigan Kidney Epidemiology and Cost Center (August 2017) 14/15

15 TABLE 12: Comorbidities Reported on Medicare Claims for Medicare Dialysis Patients Treated as of December 31 st of Each Year *1, a Medicare dialysis patients on 12/31(n) 37,306 38,479 38,764 39,555 n/a 12b Comorbidity (% yes of 12a) Infections AIDS/HIV positive Dialysis access-related Hepatitis B Hepatitis other Metastatic Pneumonia Tuberculosis Other Cardiovascular Other Cardiac arrest Cardiac dysrhythmia Cerebrovascular disease Congestive heart failure Ischemic heart disease Myocardial infarction Peripheral vascular disease * Alcohol dependence Anemia Cancer Chronic obstructive pulmonary disease Diabetes Drug dependence Gastrointestinal tract bleeding Hyperparathyroidism c Average number of comorbid conditions [*1] Based on patients with Medicare as primary insurer on 12/31 each year; See Guide, Section XV. [*2] Peripheral vascular disease includes venous, arterial and nonspecific peripheral vascular diseases. Produced by The University of Michigan Kidney Epidemiology and Cost Center (August 2017) 15/15